The following is a summary of the AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript:

Financial Performance:

• AngioDynamics reported revenue of $73 million in Q2 2025, a 9% increase year-over-year.

• Med Tech segment revenue grew 25%, contributing $31.6 million.

• Gross margin was 54.7%, slightly down from the prior year, with Med Tech gross margin at 63.7%.

• Adjusted EBITDA was $3.1 million, a significant improvement from a loss of $10,000 in the same quarter the previous year.

• The company generated $2.5 million in operating cash flow.

Business Progress:

• Strong growth in Med Tech with the Auryon platform growing 22% and solid performance particularly from mechanical thrombectomy devices AlphaVac and AngioVac showing a combined growth of 46%.

• Extended indications for NanoKnife in prostate tissue ablation and additional positive reimbursement and regulatory progress.

• Ongoing transition to outsourced manufacturing expected to generate $15 million in annualized savings by fiscal 2027.

Opportunities:

• Expansion in high-growth med tech markets is driving revenue growth, with market potential now at over $10 billion globally.

• New regulatory approvals and reimbursement pathways for products like NanoKnife in prostate treatment positively position the company for increased market penetration.

Risks:

• Potential impacts from inflationary pressures and costs associated with transitioning to outsourced manufacturing which could affect financial margins in the short term.

More details: AngioDynamics IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.